The adhesion of MM cells through molecules, such as VLA-4 or CD44, and direct contact of myeloma cells to BMSCs allow MM cells to survive the cytotoxic effects of anti-cancer therapy [28]. This evidence concerns the gene CD44 and Miyoshi myopathy.